{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:55:51Z","timestamp":1784872551840,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ecl.2018.04.013","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T01:22:26Z","timestamp":1531272146000},"page":"645-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Gastric Carcinoids"],"prefix":"10.1016","volume":"47","author":[{"given":"Simona","family":"Grozinsky-Glasberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystallenia I.","family":"Alexandraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Chatzellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Sougioultzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2018.04.013_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bpg.2013.01.002","article-title":"Gastric and duodenal neuroendocrine tumours","volume":"26","author":"O'Toole","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335595","article-title":"ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms","volume":"103","author":"Delle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ije\/dyx030","article-title":"Serum gastrin and cholecystokinin are associated with subsequent development of gastric cancer in a prospective cohort of Finnish smokers","volume":"46","author":"Murphy","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ecl.2018.04.013_bib7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4158\/EP171879.OR","article-title":"Epidemiology of gastrointestinal neuroendocrine tumors in a U.S. commercially insured population","volume":"23","author":"Broder","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2018.04.013_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ecl.2018.04.013_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.gtc.2013.01.009","article-title":"Gastric carcinoids (neuroendocrine neoplasms)","volume":"42","author":"Kidd","year":"2013","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.ecl.2018.04.013_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","article-title":"Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study","volume":"104","author":"Rindi","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ecl.2018.04.013_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cen.12476","article-title":"Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms","volume":"81","author":"Kaltsas","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2018.04.013_bib12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.12698","article-title":"Review article: the investigation and management of gastric neuroendocrine tumours","volume":"39","author":"Basuroy","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coph.2016.08.013","article-title":"Gastrin and upper GI cancers","volume":"31","author":"Hayakawa","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ecl.2018.04.013_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3892\/mco.2014.332","article-title":"Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: results from the large database of a multidisciplinary group clinical multicenter study","volume":"2","author":"O'Connor","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ecl.2018.04.013_bib16","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1677\/ERC-10-0152","article-title":"Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters","volume":"17","author":"Niederle","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ecl.2018.04.013_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1572-0241.2003.04027.x","article-title":"A\u00a050-year analysis of 562 gastric carcinoids: small tumor or larger problem?","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1365-2036.2011.04659.x","article-title":"Development of type I gastric carcinoid in patients with chronic atrophic gastritis","volume":"33","author":"Vannella","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0960-7404(03)00034-3","article-title":"Carcinoid tumors of the stomach","volume":"12","author":"Modlin","year":"2003","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000098007","article-title":"Well-differentiated gastric tumors\/carcinomas","volume":"84","author":"Ruszniewski","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s002689900026","article-title":"Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior","volume":"20","author":"Rindi","year":"1996","journal-title":"World J Surg"},{"key":"10.1016\/j.ecl.2018.04.013_bib23","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/gut.33.9.1275","article-title":"Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome","volume":"33","author":"Lehy","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.ecl.2018.04.013_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0016-5085(93)90736-V","article-title":"Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome?","volume":"105","author":"Cadiot","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ecl.2018.04.013_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/02841869309083902","article-title":"Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome","volume":"32","author":"Cadiot","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.surg.2004.06.057","article-title":"Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment","volume":"136","author":"Norton","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.ecl.2018.04.013_bib27","first-page":"766","article-title":"High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study","volume":"94","author":"Marignani","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000329043","article-title":"Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate","volume":"95","author":"Merola","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.humpath.2011.01.018","article-title":"Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms","volume":"42","author":"La","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ecl.2018.04.013_bib30","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.3748\/wjg.v19.i46.8687","article-title":"Metastatic type 1 gastric carcinoid: a real threat or just a myth?","volume":"19","author":"Grozinsky-Glasberg","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib31","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1245\/s10434-011-1652-0","article-title":"Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids","volume":"18","author":"Saund","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ecl.2018.04.013_bib32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MOG.0b013e328365efb1","article-title":"Zollinger-Ellison syndrome: recent advances and controversies","volume":"29","author":"Ito","year":"2013","journal-title":"Curr Opin Gastroenterol"},{"issue":"Suppl 3","key":"10.1016\/j.ecl.2018.04.013_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4158\/EP10379.RA","article-title":"Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice","volume":"17","author":"Newey","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2018.04.013_bib34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1365-2036.2006.03130.x","article-title":"Review article: pathogenesis and management of gastric carcinoid tumours","volume":"24","author":"Burkitt","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/PAP.0b013e31828d185d","article-title":"Neuroendocrine proliferations of the stomach: a pragmatic approach for the perplexed pathologist","volume":"20","author":"Cockburn","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ecl.2018.04.013_bib36","first-page":"671","article-title":"Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome","volume":"79","author":"D'Adda","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.ecl.2018.04.013_bib37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/gutjnl-2015-310928","article-title":"Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids","volume":"66","author":"Sundaresan","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ecl.2018.04.013_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11894-011-0225-5","article-title":"Diagnosis and management of pernicious anemia","volume":"13","author":"Annibale","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.ecl.2018.04.013_bib39","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1046\/j.1365-2036.2002.01336.x","article-title":"The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis","volume":"16","author":"Annibale","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","article-title":"Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type","volume":"242","author":"Borch","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ecl.2018.04.013_bib41","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2002.01301.x","article-title":"Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading","volume":"16","author":"Rugge","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib42","doi-asserted-by":"crossref","first-page":"G191","DOI":"10.1152\/ajpgi.00131.2006","article-title":"Role of CCN2\/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development","volume":"292","author":"Kidd","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ecl.2018.04.013_bib43","doi-asserted-by":"crossref","first-page":"28779","DOI":"10.1074\/jbc.273.44.28779","article-title":"Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B\/gastrin receptor","volume":"273","author":"Schaffer","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ecl.2018.04.013_bib44","first-page":"1039","article-title":"Haplotype analysis defines a minimal interval for the multiple endocrine neoplasia type 1 (MEN1) gene","volume":"57","author":"Debelenko","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ecl.2018.04.013_bib45","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1210\/jc.2007-2279","article-title":"A\u00a0prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors","volume":"93","author":"Berna","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2018.04.013_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2036.2001.00876.x","article-title":"Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole","volume":"15","author":"Hirschowitz","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib47","doi-asserted-by":"crossref","first-page":"8703","DOI":"10.3748\/wjg.v19.i46.8703","article-title":"Long-term follow up of endoscopic resection for type 3 gastric NET","volume":"19","author":"Kwon","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib48","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0016-5085(99)70174-5","article-title":"ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis","volume":"116","author":"Rindi","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ecl.2018.04.013_bib49","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1002\/cncr.21451","article-title":"The molecular genetics of gastroenteropancreatic neuroendocrine tumors","volume":"104","author":"Zikusoka","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ecl.2018.04.013_bib50","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/00042737-200112000-00008","article-title":"Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid","volume":"13","author":"Annibale","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ecl.2018.04.013_bib51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000342988","article-title":"Gastric neuroendocrine tumours","volume":"29","author":"Crosby","year":"2012","journal-title":"Dig Surg"},{"key":"10.1016\/j.ecl.2018.04.013_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00353739","article-title":"Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia","volume":"18","author":"Gough","year":"1994","journal-title":"World J Surg"},{"key":"10.1016\/j.ecl.2018.04.013_bib53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/EJE-12-0836","article-title":"Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study","volume":"168","author":"Thomas","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2018.04.013_bib54","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2018.04.013_bib55","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1046\/j.1365-2168.1998.00850.x","article-title":"Gastric carcinoid expresses the gastrin autocrine pathway","volume":"85","author":"Smith","year":"1998","journal-title":"Br J Surg"},{"key":"10.1016\/j.ecl.2018.04.013_bib56","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/carcin\/bgg156","article-title":"Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist","volume":"24","author":"Martinsen","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ecl.2018.04.013_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12876-017-0708-4","article-title":"Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review","volume":"17","author":"Spence","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CEG.S109123","article-title":"Autoimmune atrophic gastritis: current perspectives","volume":"10","author":"Minalyan","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.autrev.2014.01.048","article-title":"Diagnosis and classification of autoimmune gastritis","volume":"13","author":"Toh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ecl.2018.04.013_bib60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrgastro.2010.154","article-title":"Mechanisms of disease: helicobacter pylori virulence factors","volume":"7","author":"Yamaoka","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ecl.2018.04.013_bib61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.291.2.187","article-title":"Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial","volume":"291","author":"Wong","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2018.04.013_bib62","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1001\/archinte.159.15.1726","article-title":"Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association","volume":"159","author":"Centanni","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2018.04.013_bib63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2007-2134","article-title":"Autoimmune gastritis in type 1 diabetes: a clinically oriented review","volume":"93","author":"De Block","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2018.04.013_bib64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/cen.12346","article-title":"Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?","volume":"80","author":"Alexandraki","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2018.04.013_bib65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000112839","article-title":"Association of familial pernicious anaemia and hereditary haemochromatosis","volume":"119","author":"Bonafoux","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ecl.2018.04.013_bib66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000320940","article-title":"Primary hyperparathyroidism in patients with gastric carcinoid tumors type 1: an unusual coexistence","volume":"92","author":"Thomas","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4253\/wjge.v3.i7.133","article-title":"Management of early gastrointestinal neuroendocrine neoplasms","volume":"3","author":"Scherubl","year":"2011","journal-title":"World J Gastrointest Endosc"},{"key":"10.1016\/j.ecl.2018.04.013_bib68","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3748\/wjg.v18.i12.1279","article-title":"Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal","volume":"18","author":"Vannella","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ecl.2018.04.013_bib69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2003-37256","article-title":"Endoscopic mucosal resection in the management of gastric carcinoid tumors","volume":"35","author":"Ichikawa","year":"2003","journal-title":"Endoscopy"},{"key":"10.1016\/j.ecl.2018.04.013_bib70","first-page":"851","article-title":"The role of gastric resection in the management of multicentric argyrophil gastric carcinoids","volume":"108","author":"Wangberg","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.ecl.2018.04.013_bib71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1677\/ERC-07-0001","article-title":"Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ecl.2018.04.013_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the\u00a0management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib73","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000201276","article-title":"Prognosis of gastric carcinoid tumours","volume":"56","author":"Rappel","year":"1995","journal-title":"Digestion"},{"key":"10.1016\/j.ecl.2018.04.013_bib74","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/apt.12090","article-title":"Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A","volume":"36","author":"Fossmark","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2012.05143.x","article-title":"Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects","volume":"36","author":"Boyce","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ecl.2018.04.013_bib76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11894-017-0572-y","article-title":"Pathophysiology of gastric NETs: role of gastrin and menin","volume":"19","author":"Sundaresan","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.ecl.2018.04.013_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00262-010-0968-0","article-title":"2011: the immune hallmarks of cancer","volume":"60","author":"Cavallo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ecl.2018.04.013_bib78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.013_bib79","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:43:56Z","timestamp":1760175836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852918305255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0889852918305255"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.013","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastric Carcinoids","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}